CERS1 and osteosarcoma: This regimen operates by inhibiting CERS1 to attenuate mitophagy, thus compromising the mitochondrial quality control mechanisms in CDDP‐resistant osteosarcoma cells, rendering them susceptible to CDDP‐induced apoptosis.